L-Carnitine Forms: Acetyl vs. Tartrate vs. Fumarate — Why the Same Milligram Number Means Three Different Doses

L-carnitine is one of the most-studied supplements on the market and one of the most-labeled. Every mainstream retailer has a shelf of it. Most of those bottles say "1000 mg" or "500 mg" in a big number on the front. If you take a supplement whose label says "1000 mg L-carnitine" once daily, and you compare that against a clinical trial that reports "1000 mg L-carnitine daily," you probably assume you are taking the trial dose. You are not, usually. And the "L-carnitine" in the trial you are thinking of may not even be the same molecule as the one in your bottle.

L-carnitine has three retail forms in wide circulation, plus the plain L-carnitine base itself. The three are acetyl-L-carnitine (ALCAR), L-carnitine L-tartrate (LCLT), and L-carnitine fumarate. They are not interchangeable. They have different bioavailabilities, different tissue distributions, different clinical evidence bases, and different amounts of actual L-carnitine per gram of labeled compound. The label almost never tells you which one you are getting in a way that lets you do the dose math.

Here is what the four forms are, what each is actually good for based on the literature, and how to read the Supplement Facts panel to figure out whether you have the form you meant to buy at the dose you meant to take.

Why L-carnitine matters at all

L-carnitine is a quaternary ammonium compound the body makes from lysine and methionine. Its primary metabolic role is to transport long-chain fatty acids across the inner mitochondrial membrane so they can be beta-oxidized for energy. Muscle stores about 95% of total body carnitine. The rest is spread across brain, heart, kidney, and testis, with the brain fraction being small but functionally important.

Healthy people who eat meat maintain adequate carnitine stores without supplementation. Vegetarians and vegans run lower plasma and muscle carnitine and are the population where supplementation shows the clearest baseline benefit. The other populations with defensible use cases are athletes trying to increase muscle carnitine content (which requires very specific insulin-co-ingestion conditions), older adults with age-related cognitive decline (for the acetyl form specifically), and post-cardiac-event patients (for the fumarate form specifically). Everyone else is largely in "worth trying if the biomarker fits, but do not expect the moon" territory.

The interesting part is how much the form determines whether the compound will do what the label implies. Not all L-carnitines are created equal, and the label game around this is aggressive.

Base fraction: the salt-and-ester math nobody does

Before we get to the four forms, there is a math problem sitting under every carnitine label that most shoppers never notice.

L-carnitine base has a molecular weight of 161 grams per mole. When you bond it to tartaric acid to make L-carnitine L-tartrate, the tartrate half of the molecule brings its own weight, and one L-tartrate salt contains two L-carnitine molecules. The molecular weight of the salt is 472 g/mol. Do the math: 2 × 161 = 322, and 322 / 472 = 68%. In other words, 1000 mg of L-carnitine L-tartrate contains 680 mg of L-carnitine base and 320 mg of tartaric acid weight.

Acetyl-L-carnitine (as ALCAR HCl) has a molecular weight of 240 g/mol for the hydrochloride salt, and it delivers about 59-64% L-carnitine base fraction depending on the specific salt form used.

L-carnitine fumarate (2:1 molar ratio) works out to roughly 58% L-carnitine base.

Plain L-carnitine base (usually as L-carnitine HCl) delivers around 83% L-carnitine per labeled milligram after you subtract the hydrochloride weight.

The retail label almost never spells this out. A bottle that says "1000 mg L-carnitine (as L-carnitine L-tartrate)" is legally accurate if you read it as "1000 mg of the tartrate salt." It is misleading if you read it as "1000 mg of L-carnitine base." Two different products with two different form declarations can both say "1000 mg" on the front and deliver 580 mg and 830 mg of the active compound respectively. That is a 43% dose gap on identical-looking labels.

The line on the Supplement Facts panel matters. If it reads "L-carnitine (as L-carnitine L-tartrate) 1000 mg," the 1000 mg refers to the tartrate salt, not the base — the actual base is 680 mg. If it reads "L-carnitine L-tartrate 1000 mg," same thing — 1000 mg of the salt, 680 mg of base. If it reads "L-carnitine 1000 mg (from 1470 mg L-carnitine L-tartrate)," that is the honest label — the manufacturer is telling you they used 1470 mg of the tartrate to deliver 1000 mg of the L-carnitine base. Almost no product labels the honest way. The 1470-mg-tartrate label reads worse to the shopper who does not know the math.

Form one: acetyl-L-carnitine (ALCAR) — the brain form

Acetyl-L-carnitine is L-carnitine with an acetyl group bonded to the nitrogen. The acetylation is not decorative — it changes the pharmacokinetics substantially. ALCAR crosses the blood-brain barrier much more efficiently than plain L-carnitine or LCLT, and once across, the acetyl group can be donated to make acetyl-CoA (mitochondrial substrate) and to acetylate cellular proteins. This is why the ALCAR literature is dominated by neurological outcomes rather than the muscle and fat-oxidation outcomes the plain L-carnitine literature focuses on.

The evidence base for ALCAR:

• Age-related cognitive decline: the more consistent finding, with 1500-2500 mg/day for 3-6 months producing modest but replicable improvements on cognition scores in older adults with mild impairment.
• Diabetic peripheral neuropathy: several trials at 1500-3000 mg/day showing symptom improvement in the 6-12-month timeframe.
• Depressive symptoms in older adults: a signal in some meta-analyses, particularly in older cohorts, though the evidence is more heterogeneous than the cognition data.
• Male fertility (sperm motility): some evidence for ALCAR alone or paired with LCLT at combined doses of 1-3 g/day.

ALCAR does very little for muscle-recovery or fat-oxidation outcomes because it is being pulled into the CNS distribution rather than accumulating in skeletal muscle at meaningful rates. If you bought ALCAR to help post-workout soreness, you bought the wrong form.

Effective doses in the literature run 1500-3000 mg/day, and because the base fraction is around 60%, a label of 1500 mg ALCAR delivers roughly 900 mg of L-carnitine base + the acetyl functional group. Trials that report "ALCAR 2 g/day" mean 2 g of the acetyl compound, not 2 g of the base, so the label math roughly aligns if you match "trial dose of ALCAR" to "label dose of ALCAR."

Form two: L-carnitine L-tartrate (LCLT) — the muscle-recovery form

L-carnitine L-tartrate is the form the exercise-science literature settled on for muscle-specific outcomes. It is the form Kraemer and colleagues used across the mid-2000s trials showing reductions in exercise-induced muscle damage, hypoxic stress markers, and androgen-receptor upregulation at 2 g/day of LCLT (delivering ~1.36 g of L-carnitine base) taken chronically for 3-4 weeks before an exercise challenge.

The LCLT muscle-recovery signal is not about raising total muscle carnitine — a 2 g/day oral dose does not meaningfully raise muscle carnitine content in the absence of insulin co-ingestion, per the Wall/Stephens work at Nottingham. The signal is about the plasma pharmacokinetics of the tartrate salt: LCLT hits peak plasma carnitine faster and higher than plain L-carnitine or ALCAR, and the acute plasma elevation over the training window appears to be what drives the muscle-damage-attenuation effect regardless of chronic muscle content.

The evidence base for LCLT:

• Exercise-induced muscle damage markers: reductions in myoglobin, LDH, and creatine kinase post-eccentric-heavy sessions at 1-2 g/day LCLT chronic dosing.
• Perceived soreness: modest reductions in DOMS at similar doses.
• Androgen receptor density in muscle: upregulation on biopsy after 3 weeks of LCLT co-ingested with a carbohydrate load.

LCLT does very little for cognition or peripheral neuropathy — it is peripheral-distributed and does not efficiently cross the blood-brain barrier. If you bought LCLT for brain fog, you bought the wrong form.

Effective doses run 1000-3000 mg/day of the LCLT salt (delivering 680-2040 mg of L-carnitine base). The Nottingham muscle-carnitine-raising work used 2 g LCLT twice daily paired with 80 g of carbohydrate to drive insulin-mediated muscle uptake — the insulin co-ingestion is not optional for that mechanism, and it is why most gym-goers taking LCLT with a glass of water in the morning fasted are not raising their muscle carnitine content even though the dose looks right.

Form three: L-carnitine fumarate — the cardiovascular-study form

L-carnitine fumarate is the form the cardiovascular clinical trials used. It combines L-carnitine with fumaric acid, which is itself a Krebs-cycle intermediate. The cardiovascular literature includes several trials in post-myocardial-infarction populations, chronic heart-failure patients, and stable angina patients showing improvements in ejection fraction, exercise tolerance, arrhythmia burden, and mortality endpoints in some trials, though the overall evidence is heterogeneous and the meta-analyses have shifted over time as trial quality has improved.

The evidence base for L-carnitine fumarate:

• Post-myocardial-infarction outcomes: some trials showing reduced arrhythmia and improved ejection fraction at 2-6 g/day for 3-12 months, with the largest signals in smaller earlier trials.
• Stable angina exercise tolerance: modest improvements at 2 g/day.
• Chronic heart failure functional class: heterogeneous evidence; some trials positive, some null.

L-carnitine fumarate is a case where the form-specific evidence is largely a historical accident of which trials were run with which compound rather than a hard mechanistic reason fumarate outperforms tartrate in cardiac tissue. But if you are trying to reproduce the specific trial protocol your cardiologist referenced, the form specification matters — the trial specified fumarate, and generic-carnitine substitution is not the same intervention.

The base fraction for L-carnitine fumarate is around 58%, so 1000 mg of the labeled compound delivers roughly 580 mg of L-carnitine base plus the fumarate half. Effective trial doses of 2-6 g/day of the fumarate compound deliver 1.16-3.48 g of L-carnitine base — which is why "just take L-carnitine" without form specification usually undershoots the cardiac-trial dose by 40%+ if the shopper reads dose against the wrong form.

Form four: plain L-carnitine (usually as L-carnitine HCl or free base)

The plain form is the cheapest per gram of base and delivers the highest base fraction per labeled milligram (roughly 83%). Its clinical evidence base is the broadest but also the shallowest — it is the form used in general-supplementation studies rather than in the tissue-specific mechanistic work that made ALCAR, LCLT, and fumarate their own distinct compounds.

For vegetarian or vegan carnitine repletion, plain L-carnitine at 1-2 g/day of the labeled compound (delivering 830-1660 mg of base) is a defensible general-purpose choice. For a specific outcome — brain, muscle, or cardiac — one of the three specialized forms fits the evidence better.

How to read the label in 30 seconds

Turn the bottle around and read the Supplement Facts panel, not the front label:

1. Find the L-carnitine line. Note the form declaration in parentheses. If there is no form declaration, assume plain L-carnitine or L-carnitine HCl and ask why the manufacturer did not specify.
2. Note whether the milligrams describe the salt or the base. "L-carnitine (as L-carnitine L-tartrate) 1000 mg" is ambiguous by convention but usually means 1000 mg of the tartrate salt. "L-carnitine base 680 mg (from 1000 mg L-carnitine L-tartrate)" is the honest label. Assume the salt read unless the honest form is spelled out.
3. Multiply the labeled dose by the base fraction. ALCAR: ×0.60. LCLT: ×0.68. Fumarate: ×0.58. Plain HCl: ×0.83. That is the actual L-carnitine dose you are getting.
4. Match the form to the goal. Cognition or neuropathy → ALCAR. Muscle recovery / exercise damage → LCLT. Cardiac outcomes → fumarate. General repletion → plain.
5. Match the dose to the trial you are reproducing. ALCAR trials: 1500-3000 mg/day of the compound. LCLT muscle-damage: 2000-3000 mg/day. LCLT muscle-content-raising: 2000 mg twice daily with 80 g carbohydrate. Fumarate cardiac: 2000-6000 mg/day. Below the low end, you have a subclinical dose.
6. Beware of proprietary blends. A blend labeled "Carnitine Complex 1500 mg" that includes ALCAR + LCLT + tartrate in unspecified ratios is not letting you do this math. Skip it. The blends exist because they let the manufacturer sprinkle a small amount of the expensive ALCAR onto a large amount of the cheap plain form and market it as "advanced." The dose of each is too low to work.

The problem with L-carnitine on retail shelves is not that the compound does not work. Every form has a legitimate evidence base for a specific outcome. The problem is that most labels do not spec the form clearly, most shoppers do not know the base fraction math, and most bottles that promise "1000 mg L-carnitine" deliver 580-830 mg of actual carnitine base of a form that may not match the goal the shopper had in mind.

When Scythene ships L-carnitine, it will spec the form on the front of the label — no "Carnitine Complex" hedge — declare the base fraction alongside the salt-form milligrams, and pair the dose with the trial evidence it was picked to reproduce. Same three letters on the label, honest math behind them. That is the transparency bar.